On January 16, 2024 Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, reported the company and members of the Oncology Research Information Exchange Network (ORIEN) will be presenting at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium, which will be held January 18-20, 2024 in San Francisco, CA (Press release, Aster Insights, JAN 16, 2024, https://www.prnewswire.com/news-releases/aster-insights-orien-to-present-abstract-on-young-onset-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium-302034329.html [SID1234639273]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ORIEN researchers from Roswell Park Comprehensive Cancer Center will present an abstract titled, "Sex-based differences in the transcriptomic metabolic profiling in young onset colorectal cancer (YOCRC)" during the annual symposium. Aster Insights and ten ORIEN member institutions contributed to the research, which examines the differences in metabolic profiles between male and female patients with young onset colorectal cancer (YOCRC), compared with male and female patients with average onset colorectal cancer (AOCRC). The research builds upon previous studies investigating the increased incidence of YOCRC and differences in the transcriptional metabolic and immune profiles of patients based on their age and sex, respectively. The abstract utilized patient data from Aster Avatar, the best-in-class, deepest multimodal dataset for discovery research in oncology.

"This research represents a years-long, collaborative effort across Aster Insights and ORIEN to better understand the unique biological differences in patients with young onset colorectal cancer, so that we can develop more effective, personalized treatments," said Dr. Sarbajit Mukherjee, gastrointestinal medical oncologist at Roswell Park Comprehensive Cancer Center, and the primary investigator of the study. "By combining our research efforts and analyzing a rich, multimodal dataset, we can gain a more comprehensive understanding of YOCRC patients and help expedite critical discovery."

Poster presentation schedule details:

Deepak Vadehra, DO Sex-based differences in the transcriptomic metabolic profiling in young onset colorectal cancer (YOCRC) (Abstract 155)

Presentation date & time: January 20, 6:30 – 9:30 am

On January 16, 2024 Oncotelic Therapeutics, Inc (OTCQB:OTLC) reported the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients in the Special Issue Gliomas: Signaling Pathways, Molecular Mechanisms and Therapeutic Approaches (Press release, Oncotelic, JAN 16, 2024, View Source [SID1234639270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In light of our foundational discovery that elevated levels of TGF-B2 worsen mortality in various cancers, including Diffuse Midline Glioma (DMG), we have further elucidated the underlying mechanisms, particularly focusing on the impact of TGF-B2 on interferon signaling. We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

IFNGR2 is a critical component of the IFN-γ signaling pathway, playing a significant role in mediating the immune system’s defense against cancer. Its function in enhancing immune surveillance and direct anti-tumor effects making its induction an attractive target for cancer immunotherapy- including suppression of TGF-B2 by OT-101.

On January 16, 2024 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, reported that it will participate in three upcoming investor conferences in January and February (Press release, Allogene, JAN 16, 2024, View Source [SID1234639266]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

B. Riley Oncology Conference
Thursday, January 18, 2024
12:30PM PT/3:30PM ET

Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Wednesday, February 7, 2024
8:30AM PT/11:30AM ET

Oppenheimer 34th Annual Healthcare Life Sciences Conference
Wednesday, February 14, 2024
9:00AM PT/12:00PM ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.

On January 16, 2024 Vaxart, Inc. (Nasdaq: VXRT) reported that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share (Filing, 8-K, Vaxart, JAN 16, 2024, View Source [SID1234639264]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Gross proceeds are approximately $10.0 million, before deducting expenses payable by Vaxart. Vaxart intends to use the net proceeds from the offering primarily for general corporate purposes, including working capital, operating expenses and capital expenditures.

"We appreciate the financial backing by RA Capital as we continue to progress our oral pill vaccine platform," said Dr. Michael J. Finney, Vaxart’s Interim Chief Executive Officer. "We believe the clinical proof of data we have generated to date has validated our platform, which carries transformative potential to change how people get vaccinated globally. With this financing, we can continue to advance our programs, with the goal of bringing to market oral pill vaccine(s) that carries significant public health benefits."

The closing of the registered direct offering is expected to occur on or about January 18, 2024, subject to the satisfaction of customary closing conditions.

The shares of common stock are being offered by Vaxart pursuant to a shelf registration statement on Form S-3. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and is available on the SEC’s website at www.sec.gov.

Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained when available, on the SEC’s website at View Source or by contacting Vaxart Investor Relations, 170 Harbor Way, Suite 300, South San Francisco, CA 94080, by email: [email protected] or by telephone: (650) 550-3500.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On January 16, 2024 Propanc Biopharma, Inc. (OTC Pink: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, reported that a certificate of grant for the Company’s foundation patent was received from the Canadian Intellectual Property Office (Press release, Propanc, JAN 16, 2024, View Source [SID1234639263]). The foundation patent covers composition claims for the Company’s lead product candidate, PRP. In further news, the PRP dosing and method to treat cancer stem cells (CSCs) patents were validated in countries across Europe, resulting in the Company’s IP portfolio growing to 87 patents filed in major global jurisdictions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Canadian foundation patent is the final application to receive a certificate of grant in the Company’s foundation patent family (there are two divisional patents remaining citing additional inventions in the US and Mexico further dividing an original patent,). This means that grant status has been secured in every jurisdiction in which the Company has filed a foundation patent application. Propan has achieved grant status for the foundation patent in over 30 different countries across North America, Europe, Asia, the Middle East and Japan.

The PRP dosing patent is an important part of the IP portfolio covering possible future clinical dosage ranges for PRP as the Company advances into early stage clinical development. For the CSCs patent, the claims cover a method to minimize the progression of cancer in a patient who has already received a first line treatment by detecting the presence of CSCs, followed by administering PRP. The future potential clinical application describes when a patient experiences a relapse and the cancer returns after primary standard of care has been applied. Europe is considered a major global region and in 2022, the worldwide pharmaceutical market was valued at approximately $1.48 trillion by Statista.com and accounted for 23.4% of global pharmaceutical sales in 2021, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).

"The advancement of our growing IP portfolio in these major regions gives us confidence that we are leading a novel approach using proenzyme technology as a long-term therapy for the treatment and prevention of metastatic cancer from solid tumors by targeting and eradicating CSCs," said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. "Our lead product candidate, PRP, is unique from other approaches as it targets CSCs, but leaves healthy cells alone, making it less toxic compared to standard treatment approaches. Furthermore, PRP is known as differentiation therapy, which means it does not directly kill CSCs, but enforces them to return to a less malignant state so they die naturally. This means a less aggressive and toxic approach, providing a better quality of life for the patient, but we hope effective over a prolonged period, because you can treat them for longer, minimizing the threat of recurrence. We look forward to advancing PRP into the clinic, and together with our growing IP portfolio, establishing the Company as a pioneer in the way we treat this killer disease."